Overview

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.
Phase:
Phase 2
Details
Lead Sponsor:
Eisai Inc.
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Lenvatinib
Sorafenib